Manaksia Steels shares locked in 10% upper circuit

The company acquired 13.25 lakh shares of Manaksia Limited, which, too, jumped about 6 percent in the morning trade. The acquisition has increased Manaksia Steel's shareholding in Manaksia Limited to 6.10 percent from 4.08 percent.

Shares of Manaksia Steels were locked in their 10 percent upper circuit at Rs 10.93 in the morning trade on BSE on September 17, a day after the company announced the acquisition of shares of Manaksia Limited.

Shares of Manaksia jumped about 6 percent in the morning trade on BSE.

"The company has acquired 13.25 lakh shares of Manaksia Limited on September 16 through market purchase. Consequent upon the aforesaid acquisition, the revised shareholding of the company in Manaksia Limited has been increased from 4.08 percent to 6.10 percent," Manaksia Steels said in a regulatory filing.

The shares were acquired at Rs 39.65 per share and at a total consideration of Rs 5.27 crore.

The company said the shares were acquired through market purchase at the available price and accordingly the transaction was not a related party transaction.

"Manaksia Steels Limited is a promoter group company of Manaksia Limited. Promoter and promoter group of Manaksia Steels are also among the promoter/promoter group of Manaksia Limited and as such the promoter/promoter group of Manaksia Steels have an interest in Manaksia Limited," the regulatory filing said.

The promoter’s holding in Manaksia Limited has been increased from 72.91 percent to 74.93 percent due to this acquisition

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

SD Solutions

Search This Blog